Guggenheim lowers Regeneron price target, says selloff ‘overdone’
Guggenheim lowered the firm’s price target on Regeneron (REGN) to $950 from $1,200 and keeps a Buy rating on the shares. The firm, which is ...
Regeneron announces FDA acceptance of BLA for linvoseltamab
Regeneron (REGN) announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the Biologics License ...
ophthalmologytimes22h
Regeneron reveals positive results from multiple trials evaluating Eylea HD (aflibercept) injection 8 mg
Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...
Designing molecules that produce color-changing circular light for 3D displays and security printing
Certain advanced technologies, such as 3D displays, biosensing, and security printing, can utilize circularly polarized ...
Gemini With Imagen 3 Will Let Google Workspace Users Generate Images of People
In a blog post, the tech giant introduced new features for Google Workspace users. The company had earlier ditched the Gemini add-on and integrated the AI features within the Workspace subscription.